WFRF:(Engvall Jan)
Search: WFRF:(Engvall Jan) > Mangafodipir as a c...
- 10 of 269
- Previous record
- Next record
- To hitlist
- Karlsson, Jan-ErikLinköpings universitet,Avdelningen för kardiovaskulär medicin,Hälsouniversitetet,Department of Internal Medicine, County Council of Jönköping, Ryhov County Hospital, Jönköping, Sweden (author)
Mangafodipir as a cardioprotective adjunct to reperfusion therapy: a feasibility study in patients with ST-segment elevation myocardial infarction
- Article/chapterEnglish2015
Publisher, publication year, extent ...
- 2015-01-01
- European Society of Cardiology,2015
- printrdacarrier
Numbers
- LIBRIS-ID:oai:DiVA.org:liu-116549
- https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-116549URI
- https://doi.org/10.1093/ehjcvp/pvu021DOI
- http://kipublications.ki.se/Default.aspx?queryparsed=id:227533964URI
Supplementary language notes
- Language:English
- Summary in:English
Part of subdatabase
- SwePubSwePub
Classification
Notes
- Aims The aim of the present study was to examine the feasibility of applying the catalytic antioxidant mangafodipir [MnDPDP, manganese (Mn) dipyridoxyl diphosphate] as a cardioprotective adjunct to primary percutaneous coronary intervention (pPCI) in patients with ST-segment elevation (STE) myocardial infarction (STEMI). Both MnDPDP and a metabolite (Mn dipyridoxyl ethyldiamine) possess properties as mitochondrial superoxide dismutase mimetics and iron chelators, and combat oxidative stress in various tissues and conditions.Methods and resultsThe study tested MnDPDP (n ¼ 10) vs. saline placebo (n ¼ 10), given as a brief intravenous (i.v.) infusion prior to balloon inflation during pPCI in patients with STEMI. Mangafodipir waswell tolerated and did not affect heart rate or blood pressure. Despite longer ischaemic time (205 vs. 144 min, P ¼ 0.019) in theMnDPDPgroup, plasma biomarker releaseswere identical for the two groups. With placebo vs.MnDPDP, mean STE resolutions were 69.8 vs. 81.9% (P ¼ 0.224) at 6 h and 73.1 vs. 84.3% (P ¼ 0.077) at 48 h. Cardiac magnetic resonance revealed mean infarct sizes of 32.5 vs. 26.2% (P ¼ 0.406) andmeanleft ventricular (LV) ejection fractions of 41.8 vs. 47.7% (P ¼ 0.617) with placebovs.MnDPDP.More LVthrombi were detected in placebo hearts (5 of 8) than MnDPDP-treated hearts (1 of 10; P ¼ 0.011).Conclusions Mangafodipir is a safe drug for use as an adjunct to reperfusion therapy. A tendency to benefit of MnDPDP needs confirmation in a larger population. The study revealed important information for the design of a Phase II trial.
Subject headings and genre
- MEDICIN OCH HÄLSOVETENSKAP Klinisk medicin Kardiologi hsv//swe
- MEDICAL AND HEALTH SCIENCES Clinical Medicine Cardiac and Cardiovascular Systems hsv//eng
- Cardiac reperfusion injury; Primary PCI; STEMI; Oxidative stress; Mitochondrial superoxide dismutase
Added entries (persons, corporate bodies, meetings, titles ...)
- El-Saadi, WalidDepartment of Internal Medicine, County Council of Jönköping, Ryhov County Hospital, Jönköping, Sweden (author)
- Ali, MustafaDepartment of Internal Medicine, County Council of Jönköping, Ryhov County Hospital, Jönköping, Sweden; Department of Radiology, County Council of Jönköping, Jönköping, Sweden (author)
- Puskar, WernerDepartment of Radiology, County Council of Jönköping, Jönköping, Sweden (author)
- Skogvard, PatrikDepartment of Internal Medicine, County Council of Jönköping, Ryhov County Hospital, Jönköping, Sweden (author)
- Engvall, Jan EÖstergötlands Läns Landsting,Linköpings universitet,Avdelningen för kardiovaskulär medicin,Hälsouniversitetet,Fysiologiska kliniken US(Swepub:liu)janen74 (author)
- Andersson, RolfLinköpings universitet,Avdelningen för läkemedelsforskning,Hälsouniversitetet(Swepub:liu)rolan40 (author)
- Maret, EvaKarolinska Institutet (author)
- Jynge, PerLinköpings universitet,Avdelningen för läkemedelsforskning,Hälsouniversitetet,PledPharma AB, Stockholm, Sweden(Swepub:liu)perjy52 (author)
- Linköpings universitetAvdelningen för kardiovaskulär medicin (creator_code:org_t)
Related titles
- In:European Heart Journal - Cardiovascular Pharmacotherapy: European Society of Cardiology1:1, s. 39-452055-68372055-6845
Internet link
Find in a library
- European Heart Journal - Cardiovascular Pharmacotherapy (Search for host publication in LIBRIS)
To the university's database
- 10 of 269
- Previous record
- Next record
- To hitlist
Find more in SwePub
- By the author/editor
- Karlsson, Jan-Er ...
- El-Saadi, Walid
- Ali, Mustafa
- Puskar, Werner
- Skogvard, Patrik
- Engvall, Jan E
- show more...
- Andersson, Rolf
- Maret, Eva
- Jynge, Per
- show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
- MEDICAL AND HEAL ...
- and Clinical Medicin ...
- and Cardiac and Card ...
- Articles in the publication
- European Heart J ...
- By the university
- Linköping University
- Karolinska Institutet
Search outside SwePub
- Extend your search to:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - National Library Systems
- LIBRIS.kb.se
